Anti-cancer products for treating cystic fibrosis

Details Anti-cancer products for treating cystic fibrosis Anti-cancer products for treating cystic fibrosis

A - Human Necessities

61

K

A61K 38/00 (2006.01) A61K 31/00 (2006.01) A61K 31/131 (2006.01) A61K 31/15 (2006.01) A61K 31/165 (2006.01) A61K 31/175 (2006.01) A61K 31/255 (2006.01) A61K 31/282 (2006.01) A61K 31/36 (2006.01) A61K 31/439 (2006.01) A61K 31/475 (2006.01) A61K 31/66 (2006.01) A61K 31/664 (2006.01) A61K 31/675 (2006.01) A61K 31/70 (2006.01) A61K 31/704 (2006.01) A61K 31/7052 (2006.01) A61K 45/00 (2006.01) A61P 11/00 (2006.01) A61P 35/00 (2006.01) C07K 14/47 (2006.01) G01N 21/64 (2006.01)

Patent

CA 2291928

The invention concerns a novel approach for treating cystic fibrosis using, in particular, anti-cancer chemotherapy. For the treatment of cystic fibrosis it proposes the use of at least one product which when administered to a patient brings about the expression or overexpression of an ABC carrier compound, in particular glutathione carrier. Preferably, the products used are anti-cancer products whose administration brings about the expression of MRP and/or MDR protein. The invention is also applicable to the treatment of rheumatoid polyarthritis or asthma. More specifically, the compounds are selected among cyclophosphamide, aclarubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, zorubicin, pirabucin, colchicine, videsine, vinorelbine, vincristine, binblastine, azithromycin, erythromycin, ifosmamide, N-acetyl cysteine, N-acetyl lysine and/or a CFTR protein fragment comprising the NBF1 domain.

La présente invention concerne une nouvelle approche pour le traitement de la mucoviscidose, qui fait intervenir la chimiothérapie, notamment anti-cancéreuse. Elle a pour objet l'utilisation, pour le traitement de la mucoviscidose, d'au moins un produit dont l'administration à un patient conduit à l'expression ou à la surexpression d'un composé transporteur ABC, notamment transporteur de glutathion. De préférence, les produits utilisés sont des produits anti-cancéreux dont l'administration conduit à l'expression de la protéine MRP et/ou MDR. Application également au traitement de la polyarthrite rhumatoïde ou de l'asthme. Plus spécifiquement, les composés sont choisis parmi le cyclophosphamide, l'aclarubicine, la doxorubicine, la daunorubicine, l'épirubicine, l'idarubicine, la zorubicine, la pirabucine, la colchicine, la vindésine, la vinorelbine, la vincristine, la vinblastine, l'azithromycine, l'erythromcine, l'ifosfamide, la N-acétyle cystéine, la N-acétyle lysine, et/ou un fragment de la proteine CFTR comprenent le domaine NBF1.

Affiliated with

Also associated with

Rating

Anti-cancer products for treating cystic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer products for treating cystic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer products for treating cystic fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1974484